{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:03:08Z","timestamp":1773086588096,"version":"3.50.1"},"reference-count":47,"publisher":"BMJ","issue":"7","funder":[{"name":"the Key Project of Scientific and Technological Support Plan of Tianjin"},{"name":"the Key Project of Healthcare Industry of Tianjin"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,6,8]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study aims to explore the association between serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) level and saphenous vein grafts disease (SVGD) after coronary artery bypass grafting (CABG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A secondary hospital in Tianjin City, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 231 participants were included in the study. Inclusion criteria were as follows: age \u226518 years, previous CABG surgery at least 12 months ago, at least one SVG for bypass during CABG, abnormal non-invasive test results or recurrent stable angina pectoris by coronary angiography indications, and willing to participate and sign informed consent. Participants with any of the following were excluded from the study: congenital valvular disease, decompensated heart failure, anaemia defined as a haemoglobin level of &lt;12\u2009g\/dL in women or &lt;13\u2009g\/dL in men, malignant neoplasms, renal failure, severe hepatic disease, thyroid disease, acute or chronic inflammatory disease and chronic obstructive lung disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measure<\/jats:title>\n                    <jats:p>SVGD was defined as at least one SVG with significant stenosis (\u226550%). Circulating PCSK9 levels were measured using commercial ELISA kits according to the manufacturer\u2019s instructions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean PCSK9 level in the SVGD group was significantly higher than that in the patent group (275.2\u00b138.6 vs 249.3\u00b137.7, p&lt;0.01). The multivariate logistic regression model revealed a significant association between serum PCSK9 and SVGD (OR 2.08, 95% CI 1.46\u20132.95) per 1 SD increase in serum PCSK9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study is the first to identify an independent association between PCSK9 and late SVGD after adjustment for established cardiovascular risk factors. A multicentre prospective cohort study with large sample size should be conducted in the future to further research this relationship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-021951","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T10:10:48Z","timestamp":1531217448000},"page":"e021951","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Association between proprotein convertase subtilisin\/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study"],"prefix":"10.1136","volume":"8","author":[{"given":"Jing","family":"Gao","sequence":"first","affiliation":[{"name":"Logistics University of Chinese People\u2019s Armed Police Forces, Tianjin, China"},{"name":"Cardiovascular Institute, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Clinical Research Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-yong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ren","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen Heather","family":"Reilly","sequence":"additional","affiliation":[{"name":"Independent Consultant, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Logistics University of Chinese People\u2019s Armed Police Forces, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"2025121515301377000_8.7.e021951.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2025121515301377000_8.7.e021951.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu213"},{"key":"2025121515301377000_8.7.e021951.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1976"},{"key":"2025121515301377000_8.7.e021951.4","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e3182736190"},{"key":"2025121515301377000_8.7.e021951.5","first-page":"251","article-title":"Natural History of Saphenous Vein Grafts","volume":"2","author":"Gosavi","year":"2013","journal-title":"Interv Cardiol Clin"},{"key":"2025121515301377000_8.7.e021951.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00004-6"},{"key":"2025121515301377000_8.7.e021951.7","doi-asserted-by":"publisher","DOI":"10.1161\/hc4701.099730"},{"key":"2025121515301377000_8.7.e021951.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2009.06.009"},{"key":"2025121515301377000_8.7.e021951.9","first-page":"119","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"2018","author":"Ibanez","year":"2017","journal-title":"European heart journal"},{"key":"2025121515301377000_8.7.e021951.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv056"},{"key":"2025121515301377000_8.7.e021951.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv174"},{"key":"2025121515301377000_8.7.e021951.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.01.023"},{"key":"2025121515301377000_8.7.e021951.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301621"},{"key":"2025121515301377000_8.7.e021951.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054013"},{"key":"2025121515301377000_8.7.e021951.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"2025121515301377000_8.7.e021951.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"2025121515301377000_8.7.e021951.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018531"},{"key":"2025121515301377000_8.7.e021951.18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab"},{"key":"2025121515301377000_8.7.e021951.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.04.224"},{"key":"2025121515301377000_8.7.e021951.20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2016.08.038","article-title":"PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia","volume":"254","author":"Alonso","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025121515301377000_8.7.e021951.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000729"},{"key":"2025121515301377000_8.7.e021951.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(09)70486-6"},{"key":"2025121515301377000_8.7.e021951.23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2016.07.922","article-title":"Prediction of cardiovascular events with levels of proprotein convertase subtilisin\/kexin type 9: A systematic review and meta-analysis","volume":"252","author":"Vlachopoulos","year":"2016","journal-title":"Atherosclerosis"},{"key":"2025121515301377000_8.7.e021951.24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jacl.2016.08.014","article-title":"Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease","volume":"10","author":"Boyer","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2025121515301377000_8.7.e021951.25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","article-title":"Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults","volume":"25","author":"Chan","year":"2016","journal-title":"Heart Lung Circ"},{"key":"2025121515301377000_8.7.e021951.26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11883-015-0499-4","article-title":"Targeting PCSK9 for therapeutic gains","volume":"17","author":"Shapiro","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2025121515301377000_8.7.e021951.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306471"},{"key":"2025121515301377000_8.7.e021951.28","doi-asserted-by":"publisher","DOI":"10.1161\/hc0902.104353"},{"key":"2025121515301377000_8.7.e021951.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.056"},{"key":"2025121515301377000_8.7.e021951.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021993"},{"key":"2025121515301377000_8.7.e021951.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(03)00355-9"},{"key":"2025121515301377000_8.7.e021951.32","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvv178"},{"key":"2025121515301377000_8.7.e021951.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01229.x"},{"key":"2025121515301377000_8.7.e021951.34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8623"},{"key":"2025121515301377000_8.7.e021951.35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11789-017-0085-0","article-title":"PCSK9 targets important for lipid metabolism","volume":"12","author":"Schulz","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"2025121515301377000_8.7.e021951.36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106396200"},{"key":"2025121515301377000_8.7.e021951.37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025253"},{"key":"2025121515301377000_8.7.e021951.38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708098200"},{"key":"2025121515301377000_8.7.e021951.39","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.220988"},{"key":"2025121515301377000_8.7.e021951.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.04.001"},{"key":"2025121515301377000_8.7.e021951.41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008782"},{"key":"2025121515301377000_8.7.e021951.42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-\u03baB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int J Mol Med"},{"key":"2025121515301377000_8.7.e021951.43","doi-asserted-by":"publisher","DOI":"10.1002\/path.4630"},{"key":"2025121515301377000_8.7.e021951.44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"2025121515301377000_8.7.e021951.45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/clc.21988","article-title":"Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention","volume":"35","author":"Kardys","year":"2012","journal-title":"Clin Cardiol"},{"key":"2025121515301377000_8.7.e021951.46","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1253\/circj.CJ-11-0365","article-title":"Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction","volume":"75","author":"Ikenaga","year":"2011","journal-title":"Circ J"},{"key":"2025121515301377000_8.7.e021951.47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/clc.22712","article-title":"Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention","volume":"40","author":"Feng","year":"2017","journal-title":"Clin Cardiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-021951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:30:26Z","timestamp":1765841426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-021951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,10]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/bmjopen-2018-021951"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-021951","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}